These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 25104103)

  • 1. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors.
    Wilding JP
    Metabolism; 2014 Oct; 63(10):1228-37. PubMed ID: 25104103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of the kidneys in glucose homeostasis. Implication of sodium-glucose cotransporter 2 (SGLT2) in diabetes mellitus treatment].
    Girard J
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S35-S41. PubMed ID: 28577741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
    Vallon V; Thomson SC
    Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
    Raskin P
    Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.
    DeFronzo RA; Davidson JA; Del Prato S
    Diabetes Obes Metab; 2012 Jan; 14(1):5-14. PubMed ID: 21955459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes.
    Solini A; Rossi C; Mazzanti CM; Proietti A; Koepsell H; Ferrannini E
    Diabetes Obes Metab; 2017 Sep; 19(9):1289-1294. PubMed ID: 28419670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal glucose metabolism in normal physiological conditions and in diabetes.
    Alsahli M; Gerich JE
    Diabetes Res Clin Pract; 2017 Nov; 133():1-9. PubMed ID: 28866383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal glucose reabsorption inhibitors to treat diabetes.
    Bailey CJ
    Trends Pharmacol Sci; 2011 Feb; 32(2):63-71. PubMed ID: 21211857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Contribution of the kidney to glucose homeostasis].
    Segura J; Ruilope LM
    Med Clin (Barc); 2013 Sep; 141 Suppl 2():26-30. PubMed ID: 24444521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents.
    Washburn WN
    Expert Opin Ther Pat; 2012 May; 22(5):483-94. PubMed ID: 22583331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.
    Misra M
    J Pharm Pharmacol; 2013 Mar; 65(3):317-27. PubMed ID: 23356840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 inhibition: a novel prospective strategy in treatment of diabetes mellitus.
    Deshmukh AB; Patel MC; Mishra B
    Ren Fail; 2013; 35(4):566-72. PubMed ID: 23438184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
    Lapuerta P; Zambrowicz B; Strumph P; Sands A
    Diab Vasc Dis Res; 2015 Mar; 12(2):101-10. PubMed ID: 25690134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
    Jabbour SA
    Postgrad Med; 2014 Jan; 126(1):111-7. PubMed ID: 24393758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.
    Neumiller JJ; White JR; Campbell RK
    Drugs; 2010 Mar; 70(4):377-85. PubMed ID: 20205482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications.
    Gerich JE
    Diabet Med; 2010 Feb; 27(2):136-42. PubMed ID: 20546255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental type II diabetes and related models of impaired glucose metabolism differentially regulate glucose transporters at the proximal tubule brush border membrane.
    Chichger H; Cleasby ME; Srai SK; Unwin RJ; Debnam ES; Marks J
    Exp Physiol; 2016 Jun; 101(6):731-42. PubMed ID: 27164183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.
    DeFronzo RA; Norton L; Abdul-Ghani M
    Nat Rev Nephrol; 2017 Jan; 13(1):11-26. PubMed ID: 27941935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural Products as Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors.
    Blaschek W
    Planta Med; 2017 Aug; 83(12-13):985-993. PubMed ID: 28395363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.